Royal Bank Of Canada reiterated their outperform rating on shares of Merck & Co., Inc. (NYSE:MRK – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $142.00 price objective on the stock.
A number of other equities research analysts also recently issued reports on the company. Scotiabank boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research note on Thursday, December 4th. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Cantor Fitzgerald raised their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Finally, BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the company from $82.00 to $130.00 in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $127.13.
Check Out Our Latest Report on Merck & Co., Inc.
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.
Merck & Co., Inc. Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.
Insiders Place Their Bets
In other news, CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the transaction, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Merck & Co., Inc.
A number of hedge funds have recently modified their holdings of the company. J. Derek Lewis & Associates Inc. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $214,000. Purpose Unlimited Inc. bought a new position in Merck & Co., Inc. in the 4th quarter worth $11,048,000. Cornerstone Planning LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $3,085,000. Rockefeller Capital Management L.P. increased its stake in Merck & Co., Inc. by 33.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,722,146 shares of the company’s stock worth $181,274,000 after buying an additional 429,419 shares in the last quarter. Finally, Bank of New Hampshire increased its stake in Merck & Co., Inc. by 3.1% in the 4th quarter. Bank of New Hampshire now owns 9,033 shares of the company’s stock worth $951,000 after buying an additional 275 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.
Merck & Co., Inc. News Summary
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Late‑stage cholesterol pill delivered large LDL cuts (≈64.6%) and met its head‑to‑head primary endpoint — a potential new blockbuster oral option for lowering “bad” cholesterol that could materially diversify revenue beyond oncology. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
- Positive Sentiment: Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) showed proof‑of‑concept in combined post‑ and precapillary pulmonary hypertension with HFpEF — opens a foothold in a hard heart‑failure segment and supports pipeline value. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
- Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” and a $142 price target — a sizable upside vs. current levels that can support investor confidence and buying interest. Benzinga coverage
- Neutral Sentiment: Retail and media attention (e.g., Jim Cramer’s “stay the course” call) has driven momentum into Merck stock over recent months; that attention can amplify swings but is not a fundamental catalyst. Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
- Neutral Sentiment: Industry reports list Merck as a major player in the growing cutaneous squamous cell carcinoma market — underscores long‑term TAM but not an immediate stock driver. Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion
- Neutral Sentiment: New FY2026 earnings estimates and coverage updates are circulating (Erste Group Bank note) — watch revisions for guidance confirmation versus management’s FY2026 EPS range. FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
- Negative Sentiment: Analysis flags an upcoming Keytruda patent cliff and Merck’s aggressive M&A push to refill the revenue gap — a strategic risk that could pressure sentiment if deal execution or integration falls short. Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff
About Merck & Co., Inc.
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
See Also
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
